Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIMINATE: LBP-EC01 for Acute Uncomplicated UTI Caused by Drug-Resistant E. Coli
NCT05488340Phase 2Recruiting
- Sponsor
- Locus Biosciences
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Modality
- CRISPR-Cas9, Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LBP-EC01 in urinary tract infection (UTI) (5 arms), sponsored by Locus Biosciences. Primary endpoints: Levels of LBP-EC01 in urine and blood and Combined Clinical and Microbiologic Response at Day 10. Started Jul 2022; status: recruiting.
02
Drugs
LBP-EC01
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT05488340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488340.